Similar to the GBM models the combination treatments reduced the growth of the tumor cells more potently than the single treatments, suggesting that the approach to combine metabolic inhibitors along with Aurora kinase A blockers are likely applicable to a broader range of solid malignancies (Fig. S15c, d). This evidence concerns the gene AURKA and glioblastoma.